Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.70 |
| ▸ | CA12 | O43570 | 3/20 | 0.70 |
| ▸ | CA1 | P00915 | 3/20 | 0.70 |
| ▸ | CA2 | P00918 | 3/20 | 0.70 |
| ▸ | CA3 | P07451 | 3/20 | 0.70 |
| ▸ | CA4 | P22748 | 3/20 | 0.70 |
| ▸ | CA6 | P23280 | 3/20 | 0.70 |
| ▸ | CA5A | P35218 | 3/20 | 0.70 |
| ▸ | CA7 | P43166 | 3/20 | 0.70 |
| ▸ | CA9 | Q16790 | 3/20 | 0.70 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.70 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.70 |
| ▸ | AKR1B10 | O60218 | 3/20 | 0.70 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.70 |
| ▸ | DPP4 | P27487 | 2/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.70 |
| ▸ | HPGD | P15428 | 2/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.70 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4610390 | 1.00 | KDM4E (0.70) | KDM4EHSD17B10CA12CA1CA2 | |
| SCHEMBL407484 | 0.85 | KDM4E (0.58) | KDM4EHSD17B10CA12CA1CA2 | |
| SCHEMBL407485 | 0.85 | KDM4E (0.58) | KDM4EHSD17B10CA12CA1CA2 | |
| SCHEMBL29389045 | 0.85 | KDM4E (0.58) | KDM4EHSD17B10CA12CA1CA2 | |
| SCHEMBL21986697 | 0.84 | IAPP (0.71) | KDM4EHSD17B10CA12CA1CA2 | |
| SCHEMBL21986702 | 0.84 | IAPP (0.71) | KDM4EHSD17B10CA12CA1CA2 | |
| SCHEMBL17691544 | 0.84 | BACE1 (0.62) | KDM4EHSD17B10CA12CA1CA2 | |
| Hydrochloric Acid SCHEMBL27954236 | 0.83 | KDM4E (0.56) | KDM4EHSD17B10CA12CA1CA2 | |
| Caffeic Acid SCHEMBL21114743 | 0.82 | KDM4E (1.00) | KDM4EHSD17B10CA12CA1CA2 | |
| Caffeic Acid SCHEMBL3682144 | 0.82 | KDM4E (1.00) | KDM4EHSD17B10CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240229088-A1 | POLYAMINE ANALOG PRODUCING YEASTS | TECHNICAL UNIVERSITY OF DENMARK (DK) | 2024-07-11 | — | — | US | disclosed |
| CN-116574054-A | Selective estrogen receptor down regulator compound, preparation method and application | 南京中医药大学 | 2023-08-11 | — | — | CN | disclosed |
| EP-4051800-A1 | POLYAMINE ANALOG PRODUCING YEASTS | Chrysea Limited (IE) | 2022-09-07 | — | — | EP | disclosed |
| CN-114585727-A | Yeast for producing polyamine analogs | 克里希有限公司 | 2022-06-03 | — | — | CN | disclosed |
| WO-2021083869-A1 | POLYAMINE ANALOG PRODUCING YEASTS | CHRYSEA LIMITED (IE) | 2021-05-06 | — | — | WO | disclosed |
| EP-3122751-B1 | CONDENSED [1,4]DIAZEPINE COMPOUNDS AS AUTOTAXIN (ATX) AND LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION INHIBITORS | HOFFMANN LA ROCHE (CH) | 2019-10-30 | — | — | EP | disclosed |
| EP-2528897-B9 | DI-SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS | OTSUKA PHARMA CO LTD (JP) | 2015-04-22 | — | — | EP | disclosed |
| EP-2528897-B1 | DI-SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS | OTSUKA PHARMA CO LTD (JP) | 2014-10-15 | — | — | EP | disclosed |
| US-8722663-B2 | Di-substituted pyridine derivatives as anticancers | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-05-13 | — | — | US | disclosed |
| EP-2528897-A1 | DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2012-12-05 | — | — | EP | disclosed |
| US-20120283242-A1 | DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-11-08 | — | — | US | disclosed |
| EP-1781297-B1 | NOVEL BIAROMATIC COMPOUNDS THAT ACTIVATE PPAR TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RES & DEV (FR) | 2008-10-15 | — | — | EP | disclosed |
| EP-1893617-A1 | TRICYCLIC COMPOUNDS USEFUL AS SEROTONIN INHIBITORS AND 5-HT1A AGONISTS AND ANTAGONISTS | Wyeth a Corporation of the State of Delaware (US) | 2008-03-05 | — | — | EP | disclosed |
| EP-1781297-A1 | NOVEL BIAROMATIC COMPOUNDS THAT ACTIVATE PPAR TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | Galderma Research & Development, S.N.C. (FR) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006138549-A1 | TRICYCLIC COMPOUNDS USEFUL AS SEROTONIN INHIBITORS AND 5-HT1A AGONISTS AND ANTAGONISTS | WYETH (US) | 2006-12-28 | — | — | WO | disclosed |
| WO-2006018326-A1 | NOVEL BIAROMATIC COMPOUNDS THAT ACTIVATE PPAR TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283242-A1 | DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS | TPD52L2, CCNE2, CDK2 | KDM4E 719/4885HSD17B10 1944/4885CA12 4010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.